Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...

Hiroyuki Okuzawa, CEO of Japanese pharmaceutical giant Daiichi Sankyo, talks about the company's revenue driver in its latest report, and the lack of visibility from the impact of potential U.S.

Donna McMenamin is one of thousands of breast cancer patients in the UK caught up in a disagreement over costs between the ...

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Daiichi Sankyo’s optimism is driven by the strong performance of Enhertu, with related revenue soaring by 45% YoY to ¥651 billion, accounting for the majority of the company’s overall revenue increase ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Japan biopharmaceutical logistics market was valued at US$ 6.34 billion in 2024 and is expected to reach US$ 12.21 billion by 2033 at a CAGR of 7.77% during the forecast period 2025-2033.